USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: ADAPTIVE TCR CORPORATION
City: SEATTLE
State: WA
Zip+4: 98102-
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,213,074.00 4
SBIR Phase II $2,528,467.00 1

Award List:

Development of T-cell receptor repertoire profiling as a diagnostic for T1D

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert J. Livingston
Award Amount: $632,685.00
Abstract:
DESCRIPTION (provided by applicant): The goal of this Phase I project is the identification of a molecular signature in the T-cell receptor repertoire of early-stage Type 1 Diabetes (T1D) patients that distinguishes these patients from controls. At presen t, immunomodulatory therapies have not… More

Correlating TCR diversity to immune reconstitution after cord blood transplant

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert J. Livingston – 206-659-0656
Award Amount: $148,999.00
Abstract:
DESCRIPTION (provided by applicant): The goal of this Phase I project is to develop a method to objectively measure immune reconstitution following hematopoietic stem cell transplantation using direct sequencing of the T-cell repertoire. This method willbe developed using data from patients treated… More

Minimal Residual Disease Monitoring by T-cell Receptor Repertoire Profiling

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Mark J. Rieder – 206-659-0067
Award Amount: $165,191.00
Abstract:
DESCRIPTION (provided by applicant): Minimal Residual Disease Monitoring by T-cell Receptor Repertoire Profiling T-cell neoplasms are generally more aggressive and have poorer outcomes than comparable B-cell lymphomas. In addition, for many of these patients, prognosis following disease relapse is… More

Correlating TCR diversity to immune reconstitution after cord blood transplant

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: Mark J. Rieder – 206-659-0067
Award Amount: $2,528,467.00
Abstract:
DESCRIPTION (provided by applicant): Many patients requiring stem cell transplantation for hematological malignancies are unable to find a suitable HLA-matched sibling or unrelated donor. Transplants using stem cells from umbilical cord blood provide an alternative for these patients, allowing… More

SBIR TOPIC 315: DEVELOPMENT OF COMPANION DIAGNOSTICS: ENABLING PRECISION MEDICINE

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Mark Rieder – 206-659-0067
Award Amount: $266,199.00
Abstract:
Immunotherapy has emerged as a promising method to treat several cancers. In 2012 the FDA approved a new immunotherapy agent, ipilimumab, for metastatic melanoma. Ipilimumab activates T-cells and globally increases the adaptive immune response and resultsin an enhanced response to the cancer. In a… More